Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01619332 · ClinicalTrials.gov registry record · Phase 1
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
NCT01619332 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 220 participants.
The verdict
NCT01619332, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
Study Summary
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG LEZ763
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01619332
The ClinicalTrials.gov registry entry for NCT01619332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01619332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01619332 about?
NCT01619332 is a clinical study titled "Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763". This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
What is the current status of trial NCT01619332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2012-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01619332?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), LEZ763 (DRUG).
Who is sponsoring clinical trial NCT01619332?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.